Indalo Therapeutics

OverviewSuggest Edit

Indalo Therapeutics is a biopharmaceutical company discovering and developing novel integrin antagonists for patients suffering from serious fibrotic diseases, such as nonalcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF). The Company has developed a drug candidate, IDL-2965, which is an oral, selective, RGD-binding integrin antagonist that inhibits the activation of TGF-β (a fibrogenic growth factor) as well as the ability of the stiff extracellular matrix to promote fibroblast migration and survival.

TypePrivate
Founded2014
HQCambridge, MA, US
Websiteindalotherapeutics.com

Locations

Indalo Therapeutics is headquartered in
Cambridge, United States

Location Map

Latest Updates

Employees (est.) (Jun 2021)5
Cybersecurity ratingAMore

Key People/Management at Indalo Therapeutics

Scott D. Seiwert

Scott D. Seiwert

Chief Scientific Officer & Founder
Peter Barrett

Peter Barrett

Board Member
Williamson Z. Bradford

Williamson Z. Bradford

Chief Medical Officer & Founder
Rajesh Devraj

Rajesh Devraj

Board Member
Ramachandran Radhakrishnan

Ramachandran Radhakrishnan

Senior Vice President of Pharmaceutical Development
Robert Jacks

Robert Jacks

President & CEO
Show more

Indalo Therapeutics Office Locations

Indalo Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
400 Technology Square, 400 Technology Square 10th floor
Show all (1)

Indalo Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2014

Indalo Therapeutics total Funding

$9 m

Indalo Therapeutics latest funding size

$9 m

Time since last funding

4 years ago

Indalo Therapeutics investors

Indalo Therapeutics's latest funding round in August 2017 was reported to be $9 m. In total, Indalo Therapeutics has raised $9 m
Show all financial metrics

Indalo Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Indalo Therapeutics Online and Social Media Presence

Embed Graph

Indalo Therapeutics Frequently Asked Questions

  • When was Indalo Therapeutics founded?

    Indalo Therapeutics was founded in 2014.

  • Who are Indalo Therapeutics key executives?

    Indalo Therapeutics's key executives are Scott D. Seiwert, Peter Barrett and Williamson Z. Bradford.

  • How many employees does Indalo Therapeutics have?

    Indalo Therapeutics has 5 employees.

  • Who are Indalo Therapeutics competitors?

    Competitors of Indalo Therapeutics include Arch Oncology, Igyxos and Imara.

  • Where is Indalo Therapeutics headquarters?

    Indalo Therapeutics headquarters is located at 400 Technology Square, 400 Technology Square 10th floor, Cambridge.

  • Where are Indalo Therapeutics offices?

    Indalo Therapeutics has an office in Cambridge.

  • How many offices does Indalo Therapeutics have?

    Indalo Therapeutics has 1 office.